IS7051A - Lyfjasamsetningar - Google Patents
LyfjasamsetningarInfo
- Publication number
- IS7051A IS7051A IS7051A IS7051A IS7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A
- Authority
- IS
- Iceland
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101932A SE0101932D0 (sv) | 2001-05-31 | 2001-05-31 | Pharmaceutical combinations |
| PCT/SE2002/001033 WO2002096428A1 (en) | 2001-05-31 | 2002-05-29 | Pharmaceutical combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7051A true IS7051A (is) | 2003-11-26 |
Family
ID=20284321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7051A IS7051A (is) | 2001-05-31 | 2003-11-26 | Lyfjasamsetningar |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20040146498A1 (is) |
| EP (1) | EP1397139A1 (is) |
| JP (1) | JP2004532869A (is) |
| KR (1) | KR20040003029A (is) |
| CN (1) | CN100352442C (is) |
| AR (1) | AR034343A1 (is) |
| AU (1) | AU2002305952B2 (is) |
| BR (1) | BR0210034A (is) |
| CA (1) | CA2447648A1 (is) |
| CO (1) | CO5550445A2 (is) |
| CZ (1) | CZ20033246A3 (is) |
| EE (1) | EE200300589A (is) |
| HU (1) | HUP0400069A3 (is) |
| IL (1) | IL158780A0 (is) |
| IS (1) | IS7051A (is) |
| MX (1) | MXPA03010761A (is) |
| NO (1) | NO20035315D0 (is) |
| PL (1) | PL366510A1 (is) |
| RU (1) | RU2331422C2 (is) |
| SE (1) | SE0101932D0 (is) |
| SK (1) | SK14732003A3 (is) |
| TW (1) | TWI232751B (is) |
| WO (1) | WO2002096428A1 (is) |
| ZA (1) | ZA200308780B (is) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867199B2 (en) | 2000-08-21 | 2005-03-15 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapeutic use |
| JP2004346067A (ja) * | 2003-04-28 | 2004-12-09 | Mitsubishi Pharma Corp | 抗血栓薬の治療可能時間を延長するための薬剤 |
| AU2004284098B2 (en) | 2003-10-21 | 2009-07-16 | Inspire Pharmaceuticals, Inc. | Tetrahydro-furo [3,4-d] dioxole compounds and compositions and method for inhibiting platelet aggregation |
| US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| US7504497B2 (en) | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
| US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| WO2005039590A1 (en) | 2003-10-21 | 2005-05-06 | Inspire Pharmaceuticals, Inc. | Non-nucleotide compositions and method for treating pain |
| US20090075949A1 (en) * | 2004-10-25 | 2009-03-19 | Wolfgang Eisert | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| US7932376B2 (en) | 2005-05-05 | 2011-04-26 | Inspire Pharmaceuticals, Inc. | Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation |
| US9532945B2 (en) * | 2006-04-04 | 2017-01-03 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor |
| JP2010508350A (ja) | 2006-10-31 | 2010-03-18 | ヤンセン ファーマシューティカ エヌ．ベー． | Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体 |
| UA100864C2 (uk) * | 2007-12-03 | 2013-02-11 | Астразенека Аб | Спосіб лікування або запобігання аневризмі черевної аорти |
| CA2780153A1 (en) * | 2009-11-09 | 2011-05-12 | Alexion Pharmaceuticals, Inc. | Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders |
| BR112012013365A2 (pt) * | 2009-12-03 | 2016-03-01 | Astrazeneca Ab | co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriais |
| WO2011076401A1 (de) | 2009-12-23 | 2011-06-30 | Holger Schankin | Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen |
| EP2633857B1 (en) | 2009-12-23 | 2015-08-12 | ratiopharm GmbH | Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid |
| CN102653539B (zh) * | 2011-03-01 | 2014-09-17 | 秦引林 | 一种抗血小板聚集化合物及其药物组合 |
| AU2012264432A1 (en) | 2011-06-01 | 2014-01-09 | Astrazeneca Ab | Novel ticagrelor co - crystal |
| WO2014191321A1 (en) * | 2013-05-29 | 2014-12-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form |
| CN104277039B (zh) * | 2014-09-19 | 2016-06-01 | 广东东阳光药业有限公司 | 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途 |
| WO2016116942A1 (en) * | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
| CN112274519A (zh) * | 2015-01-27 | 2021-01-29 | 阿斯利康(瑞典)有限公司 | 治疗或预防具有心肌梗塞病史的患者的动脉粥样硬化血栓形成事件的方法 |
| CN106204544B (zh) * | 2016-06-29 | 2019-04-05 | 南京中观软件技术有限公司 | 一种自动提取图像中标志点位置及轮廓的方法和系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9404196D0 (sv) * | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
| TR199800019T1 (xx) * | 1995-07-11 | 1998-05-21 | Astra Pharmaceuticals Limited | Trombosit topaklanmas�n� �nleyici yeni maddeler. |
| AR005245A1 (es) * | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
| FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| TWI229674B (en) * | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| AU766089B2 (en) * | 1999-03-11 | 2003-10-09 | Du Pont Pharmaceuticals Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin |
| AR023510A1 (es) * | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
| SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
-
2001
- 2001-05-31 SE SE0101932A patent/SE0101932D0/xx unknown
-
2002
- 2002-05-20 TW TW091110514A patent/TWI232751B/zh not_active IP Right Cessation
- 2002-05-24 AR ARP020101955A patent/AR034343A1/es not_active Application Discontinuation
- 2002-05-29 CZ CZ20033246A patent/CZ20033246A3/cs unknown
- 2002-05-29 IL IL15878002A patent/IL158780A0/xx unknown
- 2002-05-29 JP JP2002592938A patent/JP2004532869A/ja active Pending
- 2002-05-29 WO PCT/SE2002/001033 patent/WO2002096428A1/en not_active Ceased
- 2002-05-29 EE EEP200300589A patent/EE200300589A/xx unknown
- 2002-05-29 AU AU2002305952A patent/AU2002305952B2/en not_active Ceased
- 2002-05-29 US US10/479,019 patent/US20040146498A1/en not_active Abandoned
- 2002-05-29 CN CNB028109120A patent/CN100352442C/zh not_active Expired - Fee Related
- 2002-05-29 HU HU0400069A patent/HUP0400069A3/hu unknown
- 2002-05-29 EP EP02733751A patent/EP1397139A1/en not_active Withdrawn
- 2002-05-29 CA CA002447648A patent/CA2447648A1/en not_active Abandoned
- 2002-05-29 KR KR10-2003-7015565A patent/KR20040003029A/ko not_active Ceased
- 2002-05-29 BR BR0210034-7A patent/BR0210034A/pt not_active IP Right Cessation
- 2002-05-29 RU RU2003133216/15A patent/RU2331422C2/ru not_active IP Right Cessation
- 2002-05-29 PL PL02366510A patent/PL366510A1/xx not_active Application Discontinuation
- 2002-05-29 MX MXPA03010761A patent/MXPA03010761A/es not_active Application Discontinuation
- 2002-05-29 SK SK1473-2003A patent/SK14732003A3/sk not_active Application Discontinuation
-
2003
- 2003-11-11 ZA ZA200308780A patent/ZA200308780B/en unknown
- 2003-11-26 IS IS7051A patent/IS7051A/is unknown
- 2003-11-28 CO CO03105239A patent/CO5550445A2/es not_active Application Discontinuation
- 2003-11-28 NO NO20035315A patent/NO20035315D0/no not_active Application Discontinuation
-
2006
- 2006-04-17 US US11/406,746 patent/US20060189584A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004532869A (ja) | 2004-10-28 |
| CO5550445A2 (es) | 2005-08-31 |
| EP1397139A1 (en) | 2004-03-17 |
| RU2003133216A (ru) | 2005-04-20 |
| SE0101932D0 (sv) | 2001-05-31 |
| HUP0400069A3 (en) | 2006-02-28 |
| IL158780A0 (en) | 2004-05-12 |
| CN100352442C (zh) | 2007-12-05 |
| TWI232751B (en) | 2005-05-21 |
| AU2002305952B2 (en) | 2007-08-09 |
| SK14732003A3 (sk) | 2004-05-04 |
| CA2447648A1 (en) | 2002-12-05 |
| HUP0400069A2 (hu) | 2004-04-28 |
| KR20040003029A (ko) | 2004-01-07 |
| PL366510A1 (en) | 2005-02-07 |
| US20040146498A1 (en) | 2004-07-29 |
| US20060189584A1 (en) | 2006-08-24 |
| AR034343A1 (es) | 2004-02-18 |
| WO2002096428A1 (en) | 2002-12-05 |
| CZ20033246A3 (cs) | 2004-02-18 |
| RU2331422C2 (ru) | 2008-08-20 |
| NO20035315D0 (no) | 2003-11-28 |
| CN1512885A (zh) | 2004-07-14 |
| ZA200308780B (en) | 2005-02-11 |
| EE200300589A (et) | 2004-02-16 |
| MXPA03010761A (es) | 2004-03-02 |
| BR0210034A (pt) | 2004-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI20011478A0 (fi) | Farmaseuttinen koostumus | |
| AR028204A1 (es) | Composiciones farmaceuticas electrohiladas | |
| FI20105657L (fi) | Farmaseuttisia koostumuksia | |
| NO20033556L (no) | Farmasöytiske formuleringer | |
| ITMI20010748A0 (it) | Composizioni farmaceutiche | |
| PL367180A1 (pl) | Trwała kompozycja farmaceutyczna | |
| NO20033384D0 (no) | Farmasöytisk formulering | |
| EE200300416A (et) | Ravimvorm | |
| FI20010780A0 (fi) | Parannetut koostumukset | |
| DK1524266T3 (da) | Farmaceutisk sammensætning | |
| IS7051A (is) | Lyfjasamsetningar | |
| BR0210619A (pt) | composição | |
| NO20035627D0 (no) | Farmasöytisk formulering | |
| NO20026123L (no) | Farmasöytiske sammensetninger | |
| FI20022128A0 (fi) | Farmaseuttinen koostumus | |
| NO20031095D0 (no) | Farmasöytiske sammensetninger | |
| DK1429753T3 (da) | Farmaceutisk sammensætning omfattende gamma-butyrobetain | |
| EE200300465A (et) | Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid | |
| NO20044164L (no) | Farmasoytiske sammensetninger | |
| EE200300378A (et) | Farmatseutiline kompositsioon | |
| EE200200689A (et) | Ravimkoostised | |
| EP1413314A4 (en) | MEDICAL COMPOSITIONS | |
| FI5468U1 (fi) | Farmaseuttinen koostumus | |
| NO20041236L (no) | Farmasoytisk formulering | |
| SE0100847D0 (sv) | Novel pharmaceutical composition |